Wasik joins Fox Chase Cancer Center as chair of pathology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Mariusz Wasik was appointed chair of the Department of Pathology at Fox Chase Cancer Center and Jeanes Hospital.

He will also serve as associate director of the Cancer Center.

Wasik joins Fox Chase from the University of Pennsylvania, where he served in various positions in the department of pathology and laboratory medicine, including director of experimental hematology, director of the Hematopathology Fellowship Training Program, and director of hematopathology. Most recently, he was the principal investigator and scientific leader of the Translational Center of Excellence for Lymphoma at Abramson Cancer Center.

Wasik’s research focuses primarily on aberrant cell signaling, the underlying genetic and epigenetic mechanisms in lymphomas, the development of new diagnostic and monitoring tools, and the identification of novel treatment approaches based on the unique biology of malignant cells. He will continue scholarly activities of this kind at Fox Chase.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login